Hypothesis
Adding IL-6 receptor blockade to methotrexate would improve ACR50 response in methotrexate-inadequate responders.
What failed
The overall arm missed its endpoint, though a seropositive subgroup showed a large and consistent effect.
Why
Population heterogeneity diluted the effect — response appears confined to a serologically defined subgroup that the trial was not stratified to detect.